Filtered By:
Condition: Ischemic Stroke
Management: National Institute for Health and Clinical Excelle

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Prognostic factors for patients with acute ischemic stroke treated by mechanical thrombectomy
【Background and Purpose】To elucidate the prognostic factors for mechanical thrombectomy (MT), we investigated (retrospectively) a series of patients with acute ischemic stroke (AIS) treated with MT in our hospital.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Katsuharu Kameda, Junji Uno, Shota Yoshida, Ryosuke Otsuji, Nice Ren, Shintaro Nagaoka, Kazushi Maeda, Yoshiaki Ikai, Hidefuku Gi Source Type: research

Challenges of implementation of the RCPCH paediatric stroke guidelines (acute management component) and how they can be overcome
In August 2017, the Royal College of Paediatric and Child Health (RCPCH) published guidelines for the management of stroke in childhood between 1 month and 18 years of age (see hyperlink). This comprehensive 169-page publication is a National Institute for Health and Care Excellence (NICE)-accredited multiprofessional evidence-based guideline that provides recommendations for the management of stroke in children and young people. A small proportion of the guideline focuses on acute ischaemic stroke management with thrombolysis. Only a small number of children will be eligible for consideration for thrombolysis; however, it...
Source: Archives of Disease in Childhood - June 17, 2022 Category: Pediatrics Authors: Byrne, S., Ram, D. Tags: Review Source Type: research

Correspondence The future of stroke therapy must not be mired by past arguments
Stroke is the leading cause of disability and the fifth leading cause of death in the UK, costing the UK economy more than £7 billion per year.1 At present, the only therapeutic approved by the UK National Institute for Health and Care Excellence (NICE) for the treatment of ischaemic stroke is thrombolysis using recombinant tissue-type plasminogen activator (rtPA). However, rtPA is only effective in patients who present within 4·5 h of stroke onset, with a number needed to treat for benefit of 3·6 before 90 min, rising to 5·9 between 3 h and 4·5 h.
Source: LANCET - August 14, 2015 Category: Journals (General) Authors: Alastair M Buchan, Hasneen G Karbalai, Brad A Sutherland Tags: Correspondence Source Type: research

Thrombectomy to be offered up to 24h after onset of stroke
NICE recommends procedure in new draft guideline Related items fromOnMedica Stroke survivors need more help taking medicine Stroke deaths falling in Europe, overall Diagnosing a transient ischaemic attack One in two women and one in three men will develop neurological disease Having a stroke doubles dementia risk
Source: OnMedica Latest News - November 26, 2018 Category: UK Health Source Type: news

NICE issues final appraisal determination on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Source: NICE Area: News In its final appraisal determination (FAD), NICE has supported the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with one or more risk factors (prior stroke or ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure).   The appeal period for this appraisal will close on 6 February 2013.
Source: NeLM - Cardiovascular Medicine - January 23, 2013 Category: Cardiology Source Type: news

NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE Area: Evidence > Guidelines NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:   . prior stroke or transient ischaemic attack . age 75 years or older . hypertension . diabetes mellitus . symptomatic heart failure.   NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

NICE recommends treatment with alteplase is started as early as possible, within 4.5 hours of onset of ischaemic stroke symptoms
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

A Business Case For Stroke Reduction Initiatives In Atrial Fibrillation: 3-Year Financial Projections For Three UK Regions
Atrial Fibrillation (AF) is a common and treatable risk factor for ischaemic stroke and vascular dementia with rising incidence. Oral anticoagulation (OAC) therapy is a well-evidenced way to prevent AF-related strokes, as supported by NICE Clinical Guidelines (CG180, 2014).
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: A Orlowski, T Jamieson, J Belsey, R Slater, J Macdonald Source Type: research

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Abstract As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures rivaroxaban (Xarelto, Bayer) to submit evidence of the clinical and cost effectiveness of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome (ACS). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cos...
Source: PharmacoEconomics - December 21, 2015 Category: Health Management Source Type: research

NICE recommends Xarelto® as a treatment option for reducing secondary events in ACS
The National Institute for Health and Care Excellence (NICE) issued its Final Appraisal Determination (FAD) recommending Xarelto 2.5mg twice daily as an effective treatment option for preventing secondary events – such as death, heart attack or stroke – following acute coronary syndrome (ACS) in patients with elevated cardiac biomarkers, without prior stroke or transient ischaemic attack (TIA). (1) The FAD is the final phase in a multi-step review process by NICE and recognises the improved patient outcomes using Xarelto as a treatment option on top of dual antiplatelet therapy;* publication of guidance is expected to follow in Q1 2015.
Source: Pharmacy Europe - January 27, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Cost effectiveness Industry News Cardiovascular medicine Legislation & regulation Patient care acs antiplatelet therapy ATLAS ACS 2 TIMI 51 Latest News TIA Xaltero Source Type: news

108appropriate anticoagulation in older adults with atrial fibrillation
Introduction: Anticoagulation is recommended to prevent stroke in atrial fibrillation. NICE Guidelines state anticoagulation should be offered to all patients with a CHADVASC of 2 and above. The ESC (European Society of Cardiology) guidelines advise falls and advanced dementia should not prevent patients from receiving anticoagulation. Furthermore, advanced age (above 75 or 80 years old) should not mean anticoagulation is withheld, especially as the risk of ischaemic stroke increases with age and comorbidities.
Source: Age and Ageing - March 27, 2018 Category: Geriatrics Source Type: research

Reply: Septic cerebral emboli as a risk factor for thrombolysis-related haemorrhagic transformation
We appreciate the opportunity to respond to Dr. Jolobe ’s letter titled ‘Septic cerebral emboli as a risk factor for thrombolysis-related hemorrhagic transformation’. Dr. Jolobe made a nice comment on our article titled ‘Risk factors of hemorrhagic transformation after intravenous thrombolysis with rt-PA in acute cerebral infarction’.1 We agree that septic cerebral emboli was a risk factor for thrombolysis-related hemorrhagic transformation as demonstrated in an early study.2 In fact, it was based on this early study and the following studies that intravenous thrombolysis is not recommended for patients with acut...
Source: QJM - January 25, 2019 Category: Internal Medicine Source Type: research

Elevated non-HDL-C/HDL-C ratio increases the 1-year risk of recurrent stroke in older patients with non-disabling ischemic cerebrovascular events: results from the Xi ’an Stroke Registry Study of China
In this study, we aimed to investigate the relationship between...
Source: BMC Geriatrics - July 5, 2023 Category: Geriatrics Authors: Zhongzhong Liu, Xuemei Lin, Lingxia Zeng, Huan Zhang, Weiyan Guo, Qingli Lu, Congli Huang, Jing Wang, Pei Liu, Qiaoqiao Chang, Mi Zhang, Yan Huo, Yan Wang, Fang Wang and Songdi Wu Tags: Research Source Type: research

Metformin may not reduce cardiovascular risk or all-cause mortality
Commentary on: Boussageon R, Supper I, Bejan-Angoulvant T, et al.. Reappraisal of metformin efficacy in the treatment of Type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012;9:268–82. Context The treatment of hyperglycaemia is considered as one of the tools for preventing cardiovascular disease in Type 1 and Type 2 diabetic (T2D) patients.1 2 Metformin is recommended as the first-line drug for T2D by most international guidelines (IDF.2005. http://www.idf.org, 2007. http://www.aace.com, http://www.diabetesjournals.org, http://www.nice.org.uk/CG66). The preference for metformin over other av...
Source: Evidence-Based Medicine - March 19, 2013 Category: Internal Medicine Authors: Monami, M. Tags: Geriatric medicine, Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Diet, Ischaemic heart disease, Diabetes Online articles Source Type: research

Euro launch of next-gen thrombectomy device announced
The European launch of a next-generation clot-removal device offering enhanced navigation through the cerebral vasculature and rapid restoration of blood flow to the brain after an ischemic stroke was announced this month at the 5th Congress of European Society of Minimally Invasive Neurological Therapy (ESMINT) in Nice, Italy. The Revive SE Thrombectomy device is by Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson. read more
Source: Articles from MedicalDesign.com - September 16, 2013 Category: Medical Equipment Tags: Business Cardiovascular Source Type: news